Caplin Point Laboratories Limited · NSE:CAPLIPOINT
Caplin Point Laboratories — H1 FY24 Earnings Presentation
20 slides from Caplin Point Laboratories's earnings presentation, November 2023
Slide 1: Earnings Presentation H1 FY24
EARNINGS PRESENTATION H1 FY24 Rated #1 in India for “Most Consistent Profitable Growth across the last 10 years” Second Largest wealth creator for the decade ending 2020* November 2023 www.caplinpoint.net #Value Research magazine – Wealth Insight June 2022 issue *The Economic Times
Slide 2: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 3: Q2 FY24 Income Statement
Q2 FY24 Income Statement Revenue Gross Profit EBITDA 15% 27% 29% YoY YoY YoY 430 246 158 407 217 139 376 194 122 Q2 FY23 Q1 FY24 Q2 FY24 Q2 FY23 Q1 FY24 Q2 FY24 Q2 FY23 Q1 FY24 Q2 FY24 EBIT PAT Earnings Per Share 32% 26% YoY YoY 146 116 15.13 127 104 13.62 111 92 12.09 Q2 FY23 Q1 FY24 Q2 FY24 Q2 FY2
Slide 4: Q2 FY24 Profit Margins
Q2 FY24 Profit Margins Gross Profit Margins (%) EBITDA Margins (%) 60.0% 36.7% 34.0% 54.8% 53.9% 32.5% Q2 FY23 Q1 FY24 Q2 FY24 Q2 FY23 Q1 FY24 Q2 FY24 EBIT Margins (%) PAT Margins (%) 33.9% 27.0% 31.2% 25.6% 29.5% 24.5% Q2 FY23 Q1 FY24 Q2 FY24 Q2 FY23 Q1 FY24 Q2 FY24 4
Slide 5: H1 FY24 Income Statement
H1 FY24 Income Statement Revenue Gross Profit EBITDA 14% 21% 24% YoY YoY YoY 838 463 296 736 383 238 H1 FY23 H1 FY24 H1 FY23 H1 FY24 H1 FY23 H1 FY24 EBIT PAT Profit Margins 27% 24% YoY YoY 273 220 57.4% 54.3% 216 178 35.4% 32.4% 32.6% 29.3% 24.2% 26.3% H1 FY23 H1 FY24 H1 FY23 H1 FY24 H1 FY23 H1 FY24
Slide 6: H1 FY24 Cash and Cash Equivalents and other Key Metrics
H1 FY24 Cash and Cash Equivalents and other Key Metrics Cash and Cash Equivalents Capital Investment Lifecycle 825 Cash Flow from 772 Operation: Rs. 129 Cr 694 194 470 284 91 223 77 73 79 65 126 47 49 46 68 101 26 26 27 8 Free Cashflow: Rs. 50 Cr FY 14 FY 15 FY 16 FY 17 FY 18 FY 19 FY 20 FY 21 FY 22
Slide 7: Leadership Team
Leadership Team Chairman Perspectives Management Team Commenting on the recent performance, Mr. C.C. Paarthipan, Chairman of Caplin Dr. Sridhar Ganesan Mr. Vivek Partheeban Point Laboratories said: • Managing • Chief Operating Director Officer “We have multiple levers of high quality and consistent
Slide 8: Q2 FY24 Highlights (Emerging Markets)
Q2 FY24 Highlights (Emerging Markets) 01 03 05 Company’s unique end to end Current breakup of revenue Company ties up with existing business model in LatAm segments at LatAm: and new third-party continues to drive robust growth manufacturers with Regulatory in top and bottom line, with new - Wholesa
Slide 9: Q2 FY24 Highlights (US and Regulated markets)
Q2 FY24 Highlights (US and Regulated markets) 01 03 05 Company’s high speed Vial Company has filed 3 Ready-To- Company’s current revenue mix filling line from new expansion Use Bag products with FDA, a remains stable with 70% from Capex commercialized, which niche segment with limited Product suppli
Slide 10: Evolution Over the Decades
Evolution Over the Decades Commences Capex expansion in multiple Work on Regulated Markets projects equaling INR 600 Incorporates Caplin Steriles Listed on Stock Started outsourcing from Injectable unit starts Started first commercial Cr. CRO wing Amaris Clinical USA Inc for launching own Exchange C
Slide 11: Research & Development Capabilities
Research & Development Capabilities 1 Caplin has 5 dedicated R&D setups (3 – DSIR approved and 2 under approval) R&D Expense (Rs. Crore) R&D Expense as a % of Operating Revenue 2 Continuous capex investment of over INR 550 Cr over last 7 years towards 85 enhanced manufacturing and R&D capabilities,
Slide 12: Revenue Break up and Manufacturing Strategy
Revenue Break up and Manufacturing Strategy Revenue by Business Segment Revenue by Channel FY23 Operating Revenue (Emerging Markets) (Emerging Markets) 25% 15% 2% 75% 25% 55% 20% 83% Africa US LATAM Generic Branded Generic Wholesale Retail Institutional Caplin covers a wide spectrum of pharmaceutica
Slide 13: Generics and Branded Generics Product Mix
Generics and Branded Generics Product Mix Non-Steroidal Antiinflammatory Antihelminthics/ Dewormer Analgesic Drugs-NSAIDS Antibiotic and Antifungal Antihypertensive drug Electrolytes 13
Slide 14: Caplin Point Structure
Caplin Point Structure 100% Caplin Point Laboratories Subsidiary Caplin Steriles Ltd wholly Caplin Steriles USA Inc owned (BSE: 524742| NSE: CAPLIPOINT) (India) subsidiary (US) Manufacturing Units: Manufacturing Unit: Distribution: • CP I: Puducherry • CP IV: Gummidipoondi • Front-end office for the
Slide 15: Manufacturing and R&D Platform
Manufacturing and R&D Platform Tamil Nadu, India Location of Plants and Facilities 11 2 10 4 1. Puducherry (CP I) 8 75 2. Gummidipoondi (CP II) 3. Chengalpattu (CP III) 3 1 4. Gummudipoondi (CP IV) 5. Chennai (CP V) CP I CP III 6. Hyderabad (CP VI) Puducherry Chengalpattu 7. Chennai (CP VII) 8. Chen
Slide 16: Strategic Investments
Strategic Investments Project Summary Facility Location Product Target Market Status Timeline CP1, Caplin Point Unit-I Suthukeny, Softgel Existing Markets Completed Q4 FY23 Puducherry Line 5 – Commissioned in Injectable Vials Caplin Steriles CP4, Oct’23. and Pre-Filled Regulated Markets Q4 FY24 Phas
Slide 17: Caplin Point's Investment Case
Caplin Point’s Investment Case Core Business to show Caplin’s core business which is focused on Latin America and Francophone Africa is expected to grow at a consistent growth steady pace with industry-average margins and benchmark cashflows US Business to Boost the Aspiration is to have exceptional
Slide 18: Experienced and Visionary Board of Directors
Experienced and Visionary Board of Directors Mr. C.C. Paarthipan Dr. Sridhar Ganesan D Sathyanarayanan Dr. C K Gariyali, IAS Dr. R Nagendran Mr S Deenadayalan Chairman Managing Director Independent Director Independent Director Independent Director Independent Director 30+ Years of experience in 35+
Slide 19: P&L for the Q2 FY24 – Consolidated
P&L for the Q2 FY24 – Consolidated Value (INR Cr) Q2 FY24 Q2 FY23 YoY (%) Q1 FY24 QoQ (%) H1 FY24 H1 FY23 YoY (%) Revenue from Operation 410.06 359.05 14.2% 395.32 3.7% 805.38 705.38 14.2% Other Income 20.43 16.48 12.04 32.47 30.42 Total Revenue 430.49 375.53 14.6% 407.36 5.7% 837.85 735.80 13.9% Co
Slide 20: Investor Relations at Caplin
INVESTOR RELATIONS AT CAPLIN Mr G Venkatram investors@caplinpoint.net CHURCHGATE PARTNERS Rajiv Pandya / Paresh Rohra caplinpoint@churchgatepartners.com 524742 CAPLIPOINT CIN: L24231TN1990PLC019053 ISIN: INE475E01026 |DUNS:86-148-4556 | WWW.CAPLINPOINT.NET ©2018, Caplin Point Laboratories Limited –
Caplin Point Laboratories — H1 FY24 Earnings Presentation on 6ix